Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer

Xiong, Qi; Qin, Bo; Xin, Lingli; Yang, Bo; Song, Qi; Wang, Yu; Zhang, Sujie; Hu, Yi

doi:10.3389/fonc.2021.659380

Cited by 20 publications

(20 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, only two patients off treatment due to oral mucositis. Compared to the AEs associated with anlotinib and immunotherapy reported in previous studies, 23 , 42 no new AEs were observed in the present study. Our results show that anlotinib and immunotherapy is well tolerated in patients with the locally advanced NSCLC.…”

Section: Discussioncontrasting

confidence: 81%

Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment

Yu¹,

Jiang²,

Yang³

et al. 2022

OTT

View full text Add to dashboard Cite

Purpose As for local advanced non-small cell lung cancer (NSCLC), synchronous radiotherapy and chemotherapy is the standard treatment mode. But for patients with progress in half a year, which means the second-line chemotherapy effect is not ideal for them. We observed the efficacy and safety of anlotinib hydrochloride combined with PD-1 blockade as the second-line treatment for those patients in this trial. Patients and Methods From January 2018 to December 2019, 57 patients with the progress of local advanced NSCLC treated with anlotinib plus PD-1 blockade until disease progression or intolerance as a result of adverse events. Patients have been assessed using computed tomography prior to treatment and during follow-up every 2 months until disease progression or death. The primary endpoint was objective response rate (ORR). The secondary endpoints included overall survival (OS), progression-free survival (PFS) and safety. Survival curves were created using the Kaplan–Meier method. Results 57 patients were enrolled. The median age was 64 years, and 61.4% of the patients were men. The ORR was 50.9% with a median OS time of 14 months and the 1-year OS rates and PFS rates were 81.8% and 33.3%, respectively. The patients with squamous cell carcinoma, no brain or liver metastases had longer PFS than patients with liver metastasis. When the PFS was calculated from the time of second treatment, the median PFS was 9 months. Most adverse events (AEs) were grade 1–3, one drug-related death was noted. Conclusion The expected outcome of this study is that anlotinib combined with PD-1 blockade has tolerable toxicity and better ORR, OS than second-line chemotherapy. The results may indicate additional treatment options for patients with progress of local advance NSCLC in half a year after standard treatment.

show abstract

Section: Discussioncontrasting

confidence: 81%

Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment

Yu¹,

Jiang²,

Yang³

et al. 2022

OTT

View full text Add to dashboard Cite

show abstract

“…Consistent with our findings, the researchers also found that combination of anlotinib and immunotherapy were most noticeable in patients with wild-type EGFR. [21] In line with this, we speculated that more advanced NSCLC patients without EGFR mutation may have survival benefit from this combination therapy, but more samples need to be enrolled and analyzed.…”

Section: Discussion：mentioning

confidence: 88%

Efficacy and safety of Anlotinib plus PD-1 blockade for the treatment of advanced non-small cell lung cancer: A Retrospective study

Pan

Dai

2022

Preprint

View full text Add to dashboard Cite

Purpose: Both anlotinib and programmed cell death protein 1(PD-1) have been demonstrated anti-tumor efficacy in non-small cell lung cancer (NSCLC) in clinical. However, the number of prospective research of this combination therapy is limited in the literature. In this retrospective study, we aim to evaluate the efficacy and safety of anlotinib plus PD-1 blockade for the treatment of advanced NSCLC patients. Methods: 40 advanced NSCLC patients who received combination treatment at traditional Chinese medicine hospital of Kunshan were selected between January 1, 2020 and December 31, 2021 and 31 eligible patients were screened for further study. Progression free survival (PFS) and overall survival (OS) were the primary end points. The safety of the combination treatment was assessed by the incidence of adverse events. Results: The combined therapeutic regimen of anlotinib and PD-1 blockade in 31 advanced NSCLC patients gained a median PFS of 6.4 months (95% CI 5.4-7.4 months) and the median overall survival(mOS) was 15.4 months (95% CI 13.4-17.4 months). Of all the eligible patients, 4 patients achieved partial respone(PR) and none of these patients achieved complete response(CR). The overall response rate(ORR) and the disease control rate(DCR) were 12.9% and 54.8% respectively. The common adverse events were fatigue, loss of appetite, nausea, hypertension and hand-foot syndrome during the treatment.Conclusion: The combination of anlotinib and PD-1 blockade has promising efficacy for the advanced NSCLC patients and the toxicity is tolerable.

show abstract

“… 30 , 31 In addition, anlotinib has been shown to have synergistic effects with chemotherapy and targeted therapies. 32 , 33 Adverse effects of anlotinib monotherapy have been shown to be manageable in previous studies. 34–36 Based on the ALTER0303 study, anlotinib has been approved as an NSCLC standard third-line treatment indication.…”

Section: Discussionmentioning

confidence: 98%

FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib

Hong¹,

Weng²,

Zhou³

et al. 2022

OTT

View full text Add to dashboard Cite

Background Fibroblast growth factor receptor (FGFR) fusions in non-small cell lung cancer (NSCLC) are small genomic events. At present, there is no standard treatment strategy for patients with NSCLC carrying an FGFR fusion. Case Presentation We report the case of a 45-year-old female patient who was diagnosed with lung adenocarcinoma and underwent right upper lobectomy and postoperative adjuvant chemotherapy. After 13 months, the patient’s lung lesions progressed. Next-generation sequencing of venous blood and lung tissues confirmed an FGFR2-ERC1 fusion, and she received chemotherapy and immunotherapy. Two months later, the patient’s lung lesions progressed again. Based on the target effect of anlotinib on FGFR, the patient was subsequently treated with anlotinib, and the progression-free survival interval exceeded 8.0 months. Conclusion These findings showed that patients with lung adenocarcinoma carrying an FGFR2-ERC1 fusion gene may benefit from anlotinib. This case provided evidence to support the use of anlotinib in the treatment of NSCLC patients with FGFR fusion gene subtypes.

show abstract

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer

Cited by 20 publications

References 46 publications

Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment

Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment

Efficacy and safety of Anlotinib plus PD-1 blockade for the treatment of advanced non-small cell lung cancer: A Retrospective study

FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib

Contact Info

Product

Resources

About